SOPHiA DDM™ for Homologous Recombination Deficiency (HRD)
Maximize insights, minimize complexity
Simplify your genomic analysis with a universal approach to HRD assessment.
HRD is a predictive biomarker that helps inform precision medicine approaches across cancer types, including ovarian cancer¹. However, testing for HRD can produce complex genomic data sets that are time-intensive to analyze.
Powered by the advanced analytics of the SOPHiA DDM™ Platform, our decentralized next-generation sequencing (NGS) applications bring clarity to clinical research decisions with accurate and timely in-house insights on HRD status.
Identify the cause and effect of HRD
We offer NGS applications that enable a comprehensive assessment of HRD status by leveraging:
Targeted sequencing of germline and somatic mutations in up to 28 HRR genes (including BRCA1 & BRCA2) to reveal the underlying cause of HRD.
A deep learning algorithm, GIInger™, that utilizes low-pass whole genome sequencing (WGS) data to recognize patterns of genomic instability as a result of HRD.
Interested in an application that investigates HRD cause, effect, or both?
Whatever your laboratory’s needs are, we have a solution for you.
Streamline your end-to-end workflow
With both bundle and dry lab applications available, our universal and flexible approach to in-house HRD analysis addresses your laboratory’s specific needs and seamlessly integrates with existing workflows.
In-house adoption is made easy with the SOPHiA DDM™ MaxCare Program, empowering laboratories to gain confidence in their results, establish workflow efficiency, and meet quality standards.
a Analysis time may vary depending on the number of samples multiplexed and server load.
Witness first-hand how the SOPHiA DDM™ Platform streamlines the determination of HRD status during this 3-minute tutorial video.
Empower your research with trusted analytics
Our applications provide direct access to the cloud-based SOPHiA DDM™ Platform, a front-end application to securely upload and analyze genomic sample data. With its user-friendly interface, visualizing and filtering relevant variants are made easy.
Trusted analytical performance and advanced features enable the detection of even the most challenging variants thanks to our proprietary algorithms, including:
- GIInger™ for genomic instability assessment.
- PEPPER™ for SNV and Indel detection.
- MUSKAT™ for gene amplification analysis, including CCNE1.
Accurate variant calling, annotation and prioritization
Rapid interpretation support and reporting
Secure storage of anonymized data
Focus on what matters with evidence-based decision support
Save time on interpretation with OncoPortal™ Plus, an add-module in SOPHiA DDM™ Platform that matches tumor molecular profiles with clinical associations and available clinical trials, leveraging expertly curated evidence powered by JAX-CKB™.
After interpretation, the flexible reporting tools enable users to prepare one-click, comprehensive reports that save time and are customizable to your needs.
Discover SOPHiA DDM™ for HRD
Our portfolio offers a range of ready-to-use applications, expertly designed to target the HRD biomarkers that matter most to your laboratory.
SOPHiA DDM™ HRD Solution
Analyze HRR mutations and genomic instability in a single workflow for a complete HRD assessment.
SOPHiA DDM™ Homologous Recombination Solutions (HRS)
Focus on the targeted sequencing of up to 28 HRR genes to identify the underlying cause of HRD across cancer types.
SOPHiA DDM™ Dx HRD Solution
Support accurate detection of HRD status in ovarian cancer patients with our CE-IVD diagnostic application.
SOPHiA DDM™ GIInger Genomic Integrity Solution
Expand identification of HRD-positive samples with the universal GIInger™ algorithm for genomic instability assessment.
What do our customers think?
“The decentralized approach of SOPHiA GENETICS has enabled us to increase our scalability and output – in less than two years, we’ve tested the HRD status of over 2,000 in-house samples. The powerful analytics of SOPHiA DDM™ have helped us to maximize genomic insights from these samples and advanced our clinical research capabilities.”
Ana Gabriela
Genomic Business Unit, Sr. Manager | Dasa, Brazil
The SOPHiA GENETICS team enabled a seamless integration of GIInger™ algorithm into our already validated in-house capture-based library preparation. We are now able to test the Genomic Integrity Index for all our ovarian cancer samples quickly, accurately, and seamlessly.
Related genomic solutions
SOPHiA DDM™ for CGP
CGP enables clinical researchers to identify actionable variants and biomarkers across hundreds of genes using a single solution.
SOPHiA DDM™ for Solid Tumors
Clinical researchers are faced with the challenge of analyzing and interpreting increasingly complex genomic datasets. We help by generating insights from next-generation sequencing (NGS) data.
SOPHiA DDM™ for Hereditary Cancers
Accurately characterize the complex mutational landscape associated with major hereditary cancer disorders.
Get in touch to find out more
Our client services team is on hand to answer any questions or schedule your live demo.
1. Miller RE, et al. Ann Oncol. 2020;31(12):1606-1622.
2. Stewart MD, et al. Oncologist. 2022;27(3):167-174
Cautionary notice
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures, unless specified otherwise. The information on the relevant pages of www.sophiagenetics.com is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact [email protected] to obtain the appropriate product information for your country of residence.